161 related articles for article (PubMed ID: 17054419)
1. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders.
Griffin JL; Nicholls AW
Pharmacogenomics; 2006 Oct; 7(7):1095-107. PubMed ID: 17054419
[TBL] [Abstract][Full Text] [Related]
2. Adipose tissue dysfunction in obesity.
Blüher M
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
[TBL] [Abstract][Full Text] [Related]
3. Lipidomics is providing new insight into the metabolic syndrome and its sequelae.
Meikle PJ; Christopher MJ
Curr Opin Lipidol; 2011 Jun; 22(3):210-5. PubMed ID: 21378565
[TBL] [Abstract][Full Text] [Related]
4. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease.
Dumas ME; Kinross J; Nicholson JK
Gastroenterology; 2014 Jan; 146(1):46-62. PubMed ID: 24211299
[TBL] [Abstract][Full Text] [Related]
5. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics - the complementary field in systems biology: a review on obesity and type 2 diabetes.
Abu Bakar MH; Sarmidi MR; Cheng KK; Ali Khan A; Suan CL; Zaman Huri H; Yaakob H
Mol Biosyst; 2015 Jul; 11(7):1742-74. PubMed ID: 25919044
[TBL] [Abstract][Full Text] [Related]
7. Nutrigenetics of the lipoprotein metabolism.
Garcia-Rios A; Perez-Martinez P; Delgado-Lista J; Lopez-Miranda J; Perez-Jimenez F
Mol Nutr Food Res; 2012 Jan; 56(1):171-83. PubMed ID: 22121097
[TBL] [Abstract][Full Text] [Related]
8. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
9. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
[TBL] [Abstract][Full Text] [Related]
10. Understanding mouse models of disease through metabolomics.
Griffin JL
Curr Opin Chem Biol; 2006 Aug; 10(4):309-15. PubMed ID: 16815732
[TBL] [Abstract][Full Text] [Related]
11. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the environmental and genetic factors influencing prevalence of metabolic syndrome in Saudi Arabia.
Gosadi IM
Saudi Med J; 2016 Jan; 37(1):12-20. PubMed ID: 26739969
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein CIII: 42 years old and even more interesting.
Ginsberg HN; Brown WV
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):471-3. PubMed ID: 21325666
[No Abstract] [Full Text] [Related]
14. [The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease].
Kravchun P; Kadykova O; Gabisoniia T
Georgian Med News; 2012 Dec; (213):26-31. PubMed ID: 23293229
[TBL] [Abstract][Full Text] [Related]
15. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment.
Quiat D; Olson EN
J Clin Invest; 2013 Jan; 123(1):11-8. PubMed ID: 23281405
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease.
Winkelmann BR; März W; Boehm BO; Zotz R; Hager J; Hellstern P; Senges J;
Pharmacogenomics; 2001 Feb; 2(1 Suppl 1):S1-73. PubMed ID: 11258203
[TBL] [Abstract][Full Text] [Related]
17. Genetics of the cardiometabolic syndrome: new insights and therapeutic implications.
Sookoian S; Pirola CJ
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):37-47. PubMed ID: 19124394
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic profiling as a useful tool for diagnosis and treatment of chronic disease: focus on obesity, diabetes and cardiovascular diseases.
Kim OY; Lee JH; Sweeney G
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):61-8. PubMed ID: 23259446
[TBL] [Abstract][Full Text] [Related]
19. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Brouwers MC; de Graaf J; van Greevenbroek MM; Schaper N; Stehouwer CD; Stalenhoef AF
Curr Opin Lipidol; 2010 Dec; 21(6):530-8. PubMed ID: 20739883
[TBL] [Abstract][Full Text] [Related]
20. The genetic basis of obesity and type 2 diabetes: lessons from the new zealand obese mouse, a polygenic model of the metabolic syndrome.
Joost HG
Results Probl Cell Differ; 2010; 52():1-11. PubMed ID: 20865367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
